rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Alector, Inc.

ALEC · Nasdaq

Health CareBiotechnologyNot moving yet

ALEC stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 3.9% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 5
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$1.8M
Officials’ trades on record
0
Institutions holding
139 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$570K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months21
Buyers · sellers0 · 4
WhoDidSharesTraded
Grace Wong-SaradPrincipal Accounting Officersold3,625at $2.514 Sep 2026filed 4 Sep 2026
Neil Lindsay BerkleyCFO & Chief Business Officersold29,251at $2.663 Sep 2026filed 4 Sep 2026
Arnon RosenthalChief Executive Officersold72,606at $2.663 Sep 2026filed 4 Sep 2026
Grace Wong-SaradPrincipal Accounting Officersold5,165at $2.673 Sep 2026filed 4 Sep 2026
Grace Wong-SaradPrincipal Accounting Officersold656at $2.752 Sep 2026filed 4 Sep 2026
Grace Wong-SaradPrincipal Accounting Officersold3,475at $1.883 Jun 2026filed 3 Jun 2026
Neil Lindsay BerkleyCFO & Chief Business Officersold19,360at $1.972 Jun 2026filed 3 Jun 2026
Grace Wong-SaradPrincipal Accounting Officersold5,709at $1.972 Jun 2026filed 3 Jun 2026
Arnon RosenthalChief Executive Officersold87,216at $1.972 Jun 2026filed 3 Jun 2026
Grace Wong-SaradPrincipal Accounting Officersold1,820at $2.6516 Apr 2026filed 17 Apr 2026
Grace Wong-SaradPrincipal Accounting Officersold1,000at $2.6510 Mar 2026filed 12 Mar 2026
Grace Wong-SaradPrincipal Accounting Officersold3,367at $2.083 Mar 2026filed 3 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders139+6 on the quarter
New · exited15 · 10
Reported value$176.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
TCG Crossover Management, LLCunchanged · filed 14 Aug 202610,000,000$20.1M00.0%
BlackRock, Inc.added · filed 7 Aug 20267,847,879$15.8M+106,634+1.4%
Nantahala Capital Management, LLCadded · filed 14 Aug 20264,318,109$8.7M+1,502,126+53.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,009,340$8.1M+330,618+9.0%
Kynam Capital Management, LPadded · filed 14 Aug 20263,808,494$7.7M+1,808,494+90.4%
Merck & Co., Inc.unchanged · filed 7 Aug 20263,545,719$7.1M00.0%
Balyasny Asset Management L.P.added · filed 14 Aug 20263,247,426$6.5M+312,173+10.6%
683 Capital Management, LLCunchanged · filed 14 Aug 20263,200,000$6.4M00.0%
D. E. Shaw & Co., Inc.reduced · filed 14 Aug 20262,959,983$5.9M-372,852−11.2%
ADAR1 Capital Management, LLCadded · filed 14 Aug 20262,883,583$5.8M+1,833,583+174.6%
31 Mar 2023 – 30 Jun 2026
122132141Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Arnon Rosenthal Company insiderChief Executive Officer · last 14 Oct 20260 · 26
Grace Wong-Sarad Company insiderPrincipal Accounting Officer · last 14 Oct 20260 · 13
Neil Lindsay Berkley Company insiderCFO & Chief Business Officer · last 14 Oct 20260 · 5
Elizabeth A. Garofalo Company insiderDirector · last 17 Jun 20260 · 0
Errol B. Desouza Company insiderDirector · last 17 Jun 20260 · 0
Kristine Yaffe Company insiderDirector · last 17 Jun 20260 · 2
Louis J. Lavigne Jr. Company insiderDirector · last 17 Jun 20260 · 0
Mark Altmeyer Company insiderDirector · last 17 Jun 20260 · 0
Paula Hammond Company insiderDirector · last 17 Jun 20260 · 2
Richard H. Scheller Company insiderDirector · last 17 Jun 20260 · 4
Sara Kenkare-Mitra Company insiderPresident and Head of R&D · last 3 Dec 20250 · 12
Marc Grasso Company insiderChief Financial Officer · last 2 Jun 20250 · 10

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-741%
Free cash flow marginFY 2025 · to 31 Dec 2025-875%
Return on capital employedFY 2025 · to 31 Dec 2025-69.7%
Debt to equityFY 2025 · to 31 Dec 20250.34×
Share count trendFY 2025 · to 20 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$65.8M
Free cash flowFY 2025 · to 31 Dec 2025−$184.1M

Analyst forecasts

No analyst forecasts yet.